Accuray and the University of Wisconsin-Madison Announce Master Research Agreement to Improve Personalized Care for Patients with Cancer
Rhea-AI Summary
Accuray (NASDAQ: ARAY) and the University of Wisconsin School of Medicine and Public Health announced a new 10-year Master Research Agreement focused on personalized cancer care using the Stellar adaptive radiation therapy platform.
The collaboration supports clinical research, education, training, and development of next-generation adaptive radiotherapy, building on UW’s role in inventing technology commercialized as Accuray’s TomoTherapy System.
Positive
- 10-year Master Research Agreement with UW School of Medicine and Public Health
- Collaboration centered on Stellar adaptive radiation therapy platform development
- Support for clinical research, education, training, and adaptive therapy innovation
- Builds on UW-originated technology behind Accuray’s TomoTherapy helical platform
Negative
- None.
News Market Reaction – ARAY
In the May 18 session, ARAY gained 8.41%, reflecting a notable positive market reaction. Argus tracked a peak move of +45.0% during that session. Our momentum scanner triggered 18 alerts that day, indicating notable trading interest and price volatility. Trading volume was elevated at 2.4x the daily average, suggesting notable buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 06 | Q3 2026 earnings | Negative | -38.5% | Q3 revenue fell 7% YoY, net loss widened, guidance withdrawn. |
| Apr 22 | Earnings date notice | Neutral | -3.1% | Announced timing and access details for upcoming Q3 results call. |
| Apr 06 | Leadership change | Positive | +0.8% | Named new SVP & Chief Commercial Officer to drive commercial strategy. |
| Feb 04 | Q2 2026 earnings | Negative | -20.7% | Q2 revenue down 12% YoY, margin compression, widened net loss and restructuring. |
| Jan 21 | Earnings date notice | Neutral | +2.5% | Set date and call details for Q2 fiscal 2026 earnings release. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent earnings releases with revenue declines and widened losses were followed by double-digit percentage share price drops, while management/housekeeping announcements saw relatively modest moves.
Over the last several months, ARAY’s news flow was dominated by weak fiscal 2026 results and restructuring. Q2 and Q3 earnings on Feb 4 and May 6 showed revenue declines and larger net losses, with 24-hour price drops of -20.68% and -38.55%. In contrast, items like earnings date notices and the Apr 6 appointment of a new Chief Commercial Officer produced only small moves. Today’s multi-year academic collaboration fits into a strategic, rather than financial, narrative alongside this challenged backdrop.
Key Terms
adaptive radiation therapy medical
dose sculpting medical
intensity-modulated radiation therapy medical
IG-IMRT medical
translational research medical
bench to bedside medical
safe harbor regulatory
Form 10-K regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
MADISON, Wis., May 15, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) and the University of Wisconsin School of Medicine and Public Health (UW SMPH) announced a new 10‑year strategic collaboration to advance personalized cancer treatments using Accuray's Stellar™ adaptive radiation therapy platform. This agreement builds on longstanding shared history of partnership between Accuray and the school to develop precision radiation therapy technologies using imaging to precisely deliver dose sculpting for cancer treatments. This newest collaboration will support clinical research, education and training, and the development of adaptive therapies that help empower medical care teams to continually raise the standard in cancer care.
"Our success depends on collaboration, innovation, and the energy that comes from addressing meaningful clinical needs for patients," said Steve La Neve, President and CEO of Accuray. "This Master Research Agreement formalizes and expands our longstanding relationship with the University of Wisconsin–Madison and grounds our innovations in real-world clinical practice and impactful patient care. By leveraging our respective strengths, we aim to extend the curative power of radiotherapy so departments of all sizes around the world can benefit from advanced adaptive therapies."
In the late 1980s, University of Wisconsin-Madison Professor of Medical Physics, Human Oncology, and Engineering Thomas "Rock" Mackie and his team invented technology that would later be commercialized as Accuray's first helical radiation delivery platform, the TomoTherapy® System. This ushered in a new era in radiation medicine, enabling clinicians for the first time to integrate helical 3D image-guidance with intensity-modulated radiation therapy (IG-IMRT), increasing treatment precision and accuracy to help improve patients' cancer care. Since its introduction, Accuray has continued to enhance the helical platform, introducing advances in image quality, speed, versatility, and workflow efficiency.
The new agreement between the UW School of Medicine and Public Health and Accuray will build on this shared history to advance the next generation of adaptive radiotherapy approaches, according to Zachary Morris, MD, PhD, professor and chair of human oncology. "At UW we have exceptionally talented innovators in radiation medicine across the spectrum from discovery science to translational and clinical research and we have a track-record of advancing discoveries to clinical practice. This agreement with Accuray is an exciting next step that will accelerate the process of translating research innovation into technologies that better serve patients, leveraging a robust academic-industry collaboration to advance personalized radiotherapy treatments," said Morris.
"This framework enables us to build on a long history of shared innovation with Accuray to deepen our collaboration, bring future innovations from bench to bedside, and create translational research and training opportunities that keep patients at the center of our work," said Nita Ahuja, MD, MBA, Dean of the UW School of Medicine and Public Health and Vice Chancellor for Medical Affairs at the University of Wisconsin–Madison.
About Accuray
Accuray is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions designed to deliver radiation treatments for even the most complex cases--while making commonly treatable cases even easier--to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in Madison,
About the University of Wisconsin School of Medicine and Public Health
The University of Wisconsin School of Medicine and Public Health is recognized as one of the nation's leading institutions in health sciences education, research, and service. Founded in 1907 as the medical school of the University of Wisconsin-Madison, in 2005 it became the nation's first school to integrate the disciplines of medicine and public health. With a deep commitment to a vision of healthy people and healthy communities, we translate discovery into application and interconnect clinical care, education and research. The school employs more than 5,600 faculty and staff and provides educational opportunities for nearly 3,000 students and postgraduate trainees. For federal fiscal year 2025, the school ranked #10 in the nation among public medical schools for NIH funding according to the Blue Ridge Institute for Medical Research. Some of the nation's leading researchers, educators, and clinicians are among the faculty, including several National Medal of Science recipients and National Academy of Science honorees.
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to expectations related to the proposed collaboration between the Company and the University of
Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.
Media Contacts
Daniel Biank
Vice President of Regulatory & Government Affairs
Accuray
dbiank@accuray.com
Robyn M. Perrin, Ph.D.
Chief Communications Officer
University of Wisconsin School of Medicine and Public Health
rmperrin@wisc.edu
View original content to download multimedia:https://www.prnewswire.com/news-releases/accuray-and-the-university-of-wisconsin-madison-announce-master-research-agreement-to-improve-personalized-care-for-patients-with-cancer-302773750.html
SOURCE Accuray Incorporated